TY - JOUR
T1 - Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis
AU - Patel, Payal
AU - Patel, Parth
AU - Bhatt, Meha
AU - Braun, Cody
AU - Begum, Housne
AU - Nieuwlaat, Robby
AU - Khatib, Rasha
AU - Martins, Carolina C.
AU - Zhang, Yuan
AU - Etxeandia-Ikobaltzeta, Itziar
AU - Varghese, Jamie
AU - Alturkmani, Hani
AU - Bahaj, Waled
AU - Baig, Mariam
AU - Kehar, Rohan
AU - Mustafa, Ahmad
AU - Ponnapureddy, Rakesh
AU - Sethi, Anchal
AU - Thomas, Merrill
AU - Wooldridge, David
AU - Lim, Wendy
AU - Bates, Shannon M.
AU - Lang, Eddy
AU - Le Gal, Grégoire
AU - Righini, Marc
AU - Wiercioch, Wojtek
AU - Schünemann, Holger J.
AU - Mustafa, Reem A.
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology.
PY - 2020/6/23
Y1 - 2020/6/23
N2 - After deep vein thrombosis (DVT) is diagnosed, prompt evaluation and therapeutic intervention are of paramount importance for improvement in patient-important outcomes. We systematically reviewed patient-important outcomes in patients with suspected DVT, including mortality, incidence of pulmonary embolism (PE) and DVT, major bleeding, intracranial hemorrhage, and postthrombotic sequelae. We searched the Cochrane Central Register of Controlled Trials, Ovid Medline, Embase for eligible studies, references lists of relevant reviews, registered trials, and relevant conference proceedings. Two investigators screened and abstracted data. Nine studies with 5126 patients were included for lower extremity DVT. Three studies with 500 patients were included for upper extremity DVT. Among patients with lower extremity DVT, 0.85% (95% confidence interval [CI], 0% to 2.10%) and 0% developed recurrent DVT and PE, respectively, at 3 months. Among patients with upper extremity DVT, 0.49% (95% CI, 0% to 1.16%) and 1.98% (95% CI, 0.62% to 3.33%) developed recurrent DVT and PE, respectively, at 3 months. No major bleeding events were reported for those anticoagulated, which is lower than in other systematic reviews. For both upper and lower extremity DVT, low pretest probability patients with a negative D-dimer had a comparable incidence of VTE at 3 months (∼1%) as patients with a negative ultrasound (US). At higher pretest probabilities, negative US testing with or without serial US appears to be the safer option. In this review, we summarized the outcomes of patients evaluated by various diagnostic pathways. In most instances, there was significant limitation due to small population size or lack of direct evidence of effects of using a specific pathway. This systematic review was registered at PROSPERO as CRD42018100502.
AB - After deep vein thrombosis (DVT) is diagnosed, prompt evaluation and therapeutic intervention are of paramount importance for improvement in patient-important outcomes. We systematically reviewed patient-important outcomes in patients with suspected DVT, including mortality, incidence of pulmonary embolism (PE) and DVT, major bleeding, intracranial hemorrhage, and postthrombotic sequelae. We searched the Cochrane Central Register of Controlled Trials, Ovid Medline, Embase for eligible studies, references lists of relevant reviews, registered trials, and relevant conference proceedings. Two investigators screened and abstracted data. Nine studies with 5126 patients were included for lower extremity DVT. Three studies with 500 patients were included for upper extremity DVT. Among patients with lower extremity DVT, 0.85% (95% confidence interval [CI], 0% to 2.10%) and 0% developed recurrent DVT and PE, respectively, at 3 months. Among patients with upper extremity DVT, 0.49% (95% CI, 0% to 1.16%) and 1.98% (95% CI, 0.62% to 3.33%) developed recurrent DVT and PE, respectively, at 3 months. No major bleeding events were reported for those anticoagulated, which is lower than in other systematic reviews. For both upper and lower extremity DVT, low pretest probability patients with a negative D-dimer had a comparable incidence of VTE at 3 months (∼1%) as patients with a negative ultrasound (US). At higher pretest probabilities, negative US testing with or without serial US appears to be the safer option. In this review, we summarized the outcomes of patients evaluated by various diagnostic pathways. In most instances, there was significant limitation due to small population size or lack of direct evidence of effects of using a specific pathway. This systematic review was registered at PROSPERO as CRD42018100502.
UR - http://www.scopus.com/inward/record.url?scp=85086930215&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2020001558
DO - 10.1182/bloodadvances.2020001558
M3 - Review article
C2 - 32569377
AN - SCOPUS:85086930215
SN - 2473-9529
VL - 4
SP - 2779
EP - 2788
JO - Blood Advances
JF - Blood Advances
IS - 12
ER -